Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights
CINCINNATI, May 12, 2023 (GLOBE NEWSWIRE) — Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced its financial results for the quarter ended March 31, 2023 and provided an update on recent business developments and Company progress. Blue Water Biotech is a biological and pharmaceutical technology company developing multiple preclinical vaccine candidates across various infectious diseases and owns the FDA-approved benign hyperplasia (“BPH”) asset, ENTADFI®.
Related news for (BWV)
- Historical Regulatory Filing Deficiences Continue to Stifle Psycheceutical Biosciences
- Psycheceutical Bioscience Strategically Pivots Into the Brain-Computer Interface (BCI) Space
- Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders
- Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™
- Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company